Molecule Information

General Information of the Molecule (ID: Mol01978)

Name	Purinergic receptor P2Y12 (P2RY12) ,Homo sapiens
Synonyms	P2RY12; HORK3 Click to Show/Hide
Molecule Type	Protein
Gene Name	P2RY12
Gene ID	64805
Location	chr3:151,336,843-151,384,753[-]
Sequence	MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIFFQIRSKSNFI IFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTFVCQVTSVIFYFTMYISISFLGLITI DRYQKTTRPFKTSNPKNLLGAKILSVVIWAFMFLLSLPNMILTNRQPRDKNVKKCSFLKS EFGLVWHEIVNYICQVIFWINFLIVIVCYTLITKELYRSYVRTRGVGKVPRKKVNVKVFI IIAVFFICFVPFHFARIPYTLSQTRDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFF LCKSFRNSLISMLKCPNSATSLSQDNRKKEQDGGDPNEETPM Click to Show/Hide
Function	Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation. Click to Show/Hide
Uniprot ID	P2Y12_HUMAN
Ensembl ID	ENSG00000169313
HGNC ID	HGNC:18124
*Click to Show/Hide the Complete Species Lineage*
Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Approved Drug(s)

1 drug(s) in total

Click to Show/Hide the Full List of Drugs

Clopidogrel

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Disease Class: Hypo-attenuated leaflet thickening			[1]
Resistant Disease	Hypo-attenuated leaflet thickening [ICD-11: BD10.2]		Disease Info
Resistant Drug	Clopidogrel		Drug Info
Molecule Alteration	SNP	rs2046934+rs12637988+rs16863336+rs6798347+rs16863323+rs9859538+rs16846673+rs6809699+rs6785930+rs5853517+rs10935838
Experimental Note	Identified from the Human Clinical Data
Mechanism Description	We thoroughly genotyped 34 SNPs and 8 SNPs that have been reported for clopidogrel and aspirin resistance. A total of 148 patients were enrolled. There were 15 patients demonstrating signs of HALT. Patients with HALT had a higher rate of atrial fibrillation (AF) pre-TAVR (33.3 vs. 7.5%, P = 0.01).

References

Ref 1	Gene polymorphisms in dual antiplatelet therapy and the presence of hypo-attenuated leaflet thickening after transcatheter aortic valve replacement .J Thromb Thrombolysis. 2018 Apr;45(3):463-465. doi: 10.1007/s11239-018-1636-z. 10.1007/s11239-018-1636-z